Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ENTX
ENTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ENTX News
Entera Bio Reports Preclinical Data for EB612 and EB618
1d ago
Newsfilter
Entera Bio Hosts KOL Roundtable on EB613 for Osteoporosis
Apr 20 2026
Newsfilter
Entera Bio Secures $10 Million in Private Placement Financing
Apr 06 2026
Newsfilter
Entera Bio Secures $10 Million in Private Placement Financing
Apr 06 2026
PRnewswire
Entera Bio Secures Private Placement Financing
Apr 06 2026
NASDAQ.COM
Entera Bio Secures $10M in Private Placement Agreement
Apr 02 2026
seekingalpha
Entera Bio Reports FY 2025 Financial Results
Mar 27 2026
seekingalpha
Entera Bio Reports 2025 Financial Results and Key Developments
Mar 27 2026
Newsfilter
Entera Bio Submits Clinical Amendment for EB613
Mar 04 2026
Newsfilter
Entera Bio Shares Surge 15.71% After SEC Filing by Director
Feb 19 2026
Benzinga
Entera Bio Board Members Increase Shareholdings
Feb 11 2026
stocktwits
Entera Bio Plans Final EB613 Protocol Submission to FDA in Q1 2026
Jan 21 2026
Globenewswire
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
Jan 14 2026
NASDAQ.COM
Entera Receives FDA Qualification of Total Hip BMD as a Key Endpoint for Osteoporosis Drug Development
Dec 26 2025
Newsfilter
Entera Bio Reports Financial Results and Business Developments for Q3 2025
Nov 14 2025
Newsfilter
Entera Bio Unveils Promising New Clinical Results from EB613 Phase 2 Trial Showing Notable Bone Density Gains in Early Postmenopausal Women
Oct 23 2025
Newsfilter
Show More News
